Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II

NCT00096031 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00096031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00096031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2004
Completion date
January 31, 2010
Enrollment
63 (actual)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer